세계의 인실리코 Drug Discovery 시장 규모는 2023년에 29억 달러로 평가되며, 예측 기간(2025-2032년)의 CAGR은 11.0%로, 2024년 32억 2,000만 달러에서 2032년에는 74억 2,000만 달러로 성장할 전망입니다.
인실리코 Drug Discovery 시장은 Drug Discovery 데이터량의 증가와 바이오인포매틱스 기술의 발전으로 2023-2030년 큰 폭으로 성장할 것으로 전망됩니다. 이 시장은 인실리코 전략을 신약 타깃 발굴, 후보 분자 개발, 결합 특성 최적화에 활용하고 있습니다. 재입원율과 의료 실수를 최소화하는 데 초점을 맞춘 바이오마커 식별 증가는 시장 확대를 더욱 촉진할 것으로 예상됩니다. 계산생물학 및 비용 효율적인 인실리코 설계 서비스의 눈부신 발전으로 인해 시장의 매력은 더욱 커지고 있습니다. 그러나 가격 압박과 오픈소스 소프트웨어의 가용성 등의 문제는 성장을 저해할 수 있는 요인으로 작용할 수 있습니다. 전반적으로 제약회사의 신약개발 프로젝트와 연구 활동의 급증은 시장 참여자들에게 큰 비즈니스 기회를 제공합니다.
Global Insilico Drug Discovery Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.22 billion in 2024 to USD 7.42 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).
The in-silico drug discovery market is poised for significant growth from 2023 to 2030, driven by the increasing volume of drug discovery data and advancements in bioinformatics technologies. This market leverages in-silico strategies to identify drug targets, develop candidate molecules, and optimize their binding properties. The projected rise in biomarker identification, coupled with a focus on minimizing readmission rates and medical errors, further supports market expansion. Significant advancements in computational biology and cost-effective in-silico designing services enhance market appeal. However, challenges such as pricing pressures and the availability of open-source software may hinder growth. Overall, the surge in drug discovery projects and research activity within pharmaceutical organizations presents considerable opportunities for market players.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Insilico Drug Discovery Market Segmental Analysis
Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Insilico Drug Discovery Market
The global in-silico drug discovery market is expected to experience significant growth in the coming years, primarily driven by advancements in biomarker identification. Additionally, there is a growing emphasis on reducing readmission rates and minimizing medical errors, which further fuels this demand. Innovations in computational technologies within computational biology and enhancements in in-silico drug discovery methodologies also contribute substantially to market expansion. These factors collectively create a robust environment that encourages the adoption of in-silico approaches, ultimately transforming the drug discovery landscape and meeting the evolving needs of the healthcare sector.
Restraints in the Global Insilico Drug Discovery Market
A significant challenge facing the Global Insilico Drug Discovery market is its inherently short lifespan, which serves as a primary restraint. The analysis durations for this technology can vary from tens to hundreds of nanoseconds, contingent upon the complexity of the systems being evaluated and the computational resources available. This brevity poses a substantial issue, as the time frames-ranging from a few milliseconds to several seconds-are often insufficient for precise predictions of protein folding. Consequently, this limitation may hinder the sampling of an adequate number of protein conformations, potentially impacting the accuracy and reliability of drug discovery outcomes.
Market Trends of the Global Insilico Drug Discovery Market
The global in-silico drug discovery market is witnessing significant growth, primarily fueled by the rising adoption of cloud-based solutions that enhance computational capabilities for pharmaceutical researchers. This trend allows for scalable and adaptive computing environments, empowering researchers with virtually unlimited processing power to accelerate drug development processes. Notably, platforms like BT's Cloud Compute life sciences service offer tailored applications that cater to various stages of the drug discovery value chain, enabling seamless compatibility across diverse pipelines. As companies increasingly prioritize tailored solutions, the market is set to expand, driving innovation and efficiency in drug discovery efforts.